Identification of TAPBPL as a novel negative regulator of T-cell function.

EMBO Mol Med · 2021 · PMC8103088 · PMID 33938620

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Anti‐hTAPBPL mAb at 25 and 50 μg doses inhibited tumor growth in the model although the differences did not reach statistical significance for most time points; conversely, mAb at 100 μg dose significantly inhibited tumor growth (Fig 7D and Fig EV5C ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.